Skip to Content
COVID-19 Resources
Developmental Therapeutics Program (DTP)
Contact DTP
Show menu
Search this site
Last Updated: 03/09/21

Rosemarie Aurigemma, Ph.D.

Rosemarie Aurigemma, Ph.D., Acting Associate Director

Acting Associate Director

Developmental Therapeutics Program

Developmental Therapeutics Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
NCI Shady Grove
9609 Medical Center Drive, Rm 4W610
Bethesda, MD 20892-9735
Rockville, MD 20850 (for courier delivery)
240-276-5465
aurigemr@mail.nih.gov

Dr. Aurigemma has been a programmatic leader in drug development for over 20 years. Her tenure as the Deputy Associate Director of DTP resulted in the launch of the Stepping Stones preclinical development program as well as the initiation and expansion of biopharmaceutical manufacturing support for adoptive cell therapies. She was appointed as Acting Associate Director of the DCTD Developmental Therapeutics Program in January 2021.

Before joining NCI in 2017, Dr. Aurigemma served as Chief of the Drug Development Section in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, NIH, where she directed programs to advance new therapies for infectious diseases of public health and biodefense concern such as influenza, antibiotic resistant infections, dengue fever, Ebola and anthrax. During that time, nearly two dozen clinical trials for new therapeutics were initiated with several products reaching market approval and placement in the federal Strategic National Stockpile.

Dr. Aurigemma previously served as Program Director in the Biological Resources Branch of DTP where she managed a portfolio focused on development of biological cancer therapies and resulting in the advancement of numerous biopharmaceutical products into phase I clinical trials for cancers such as glioblastoma multiforma and ovarian cancer. Prior to joining NIH, Dr. Aurigemma held positions as Research and Discovery scientist and Clinical Research Manager in the private biotechnology sector, working to develop new drugs to treat cancer, diabetes and other diseases. Dr. Aurigemma holds a Ph.D. in Microbiology from Colorado State University and a B.S. in Biology from Cornell University.

About the Acting Associate Director

Rosemarie Aurigemma, Ph.D. Rosemarie Aurigemma, Ph.D., has been a programmatic leader in drug development for over 20 years. Her tenure as the Deputy Associate Director of DTP resulted in the launch of the Stepping Stones preclinical development program as well as the initiation and expansion of biopharmaceutical manufacturing support for adoptive cell therapies. She was appointed as Acting Associate Director of the DCTD Developmental Therapeutics Program in January 2021. More…